Mydecine Innovations Group Inc. (OTCMKTS:MYCOF – Get Free Report) shares were up 7,981.5% during trading on Monday . The company traded as high as $0.2182 and last traded at $0.2182. Approximately 166 shares were traded during trading, a decline of 98% from the average daily volume of 6,711 shares. The stock had previously closed at $0.0027.
Mydecine Innovations Group Stock Up 7,981.5%
The stock has a fifty day moving average price of $0.12 and a two-hundred day moving average price of $0.04.
Mydecine Innovations Group Company Profile
Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.
Read More
- Five stocks we like better than Mydecine Innovations Group
- Do not delete, read immediately
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Can Any Expenses Be Deducted From Capital Gains Tax?
- The Last Gold Bull Market
Receive News & Ratings for Mydecine Innovations Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mydecine Innovations Group and related companies with MarketBeat.com's FREE daily email newsletter.
